PATENT CLAIM ANALYSIS

Application Number: 15747642
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "450000"]

Abstract:
A method for the targeted delivery of the active generic antiproliferative and anti-inflammatory agents gemcitabine, paclitaxel and/or curcumin preferentially or exclusively to antigen-presenting cells (APCs) of the immune system by means of encapsulation into a lipid-based nanocarrier, the CLR-TargoSphere, which is surface-labeled with a Fucose-derivative ligand that exclusively targets C-type lectin receptors (CLRs) on APCs to deliver the active agents intracellularly to myeloid dendritic cells (mDCs), circulating monocytes, macrophages, and tumor-associated macrophages (TAMs) as well as cytotoxic T lymphocytes (CTLs).

Claim (Index 12):
The nanocarrier for the use of  claim 11 , wherein said myeloid antigen-presenting cell is selected from the group consisting of myeloid dendritic cells, cytotoxic T lymphocytes, circulating monocytes, macrophages, and tumor-associated macrophages.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.44776
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11221179', '15460701', '13279766', '14233527', '14959497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7413484305271882
- 35 USC 102 Novelty (BERT): 0.4940609328127182
- Combined Prediction Score: 0.7166196807557412
- Mean Citation Score: 192.755482
- Max Citation Score: 194.39374
- Similarity Product: 125.34847990304708

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test